Vaccines May Cut Heart Disease Risk

Vaccination against respiratory infections is being positioned as a potential tool for reducing cardiovascular disease risk as European policymakers prepare a new health strategy.

EU lawmakers weigh a draft cardiovascular plan

The European Parliament’s SANT Committee released a draft report on an EU cardiovascular diseases strategy (2025/2132 INI) on 19 January 2026. While the document outlines several preventive measures, it omits mention of immunisation’s role in lowering heart‑related events. This gap contrasts with the EU Safe Hearts Plan, which explicitly acknowledges that protecting against respiratory pathogens can help curb cardiovascular incidents.

Members of the European Parliament are currently reviewing the draft, with a vote expected in plenary by mid‑June. Advocates hope the discussion will incorporate the broader health benefits of vaccines, especially as recent data highlight the link between respiratory infections and heart complications.

Policy dialogue highlights vaccine investments

On 18 March, the Active Citizenship Network – the EU branch of the Italian NGO Cittadinanzattiva – hosted a policy dialogue in Brussels. The event, titled “Council recommendation on the value of immunisation against respiratory infections: a step towards an EU Respiratory Health Plan,” brought together experts, civil‑society representatives, and EU officials.

During the session, participants noted that the European Commission has earmarked €225 million for next‑generation influenza vaccines. These candidates aim to cover a broader spectrum of strains, respond quickly to emerging pandemic variants, and simplify administration. In a related move, the European Medicines Agency recently recommended marketing authorisation for the EU’s first combined vaccine targeting seasonal flu and COVID‑19 in people aged 50 and older.

Stakeholders, including scientific societies and patient groups, urged MEPs to consider these developments when finalising the cardiovascular strategy. The Steering Group on Prevention of Respiratory Infections, of which the Active Citizenship Network is a member, submitted amendments aligned with its manifesto. Simultaneously, the EU Working Group on Respiratory Care launched a Call to Action aimed at embedding respiratory health needs within a unified European framework.

Cypriot MEP Michalis Hadjipantela (EPP Group) hosted the dialogue, supported by the MEPs Interest Group “European Patients’ Rights & Cross‑border Healthcare.” The gathering was part of the EU project “Advancing Respiratory Care at the EU Level,” which benefits from unconditional backing by Pfizer.

Linking respiratory vaccines to heart health matters

Research increasingly shows that acute respiratory infections can precipitate cardiovascular events. Inflammation, increased blood clotting, and stress on the heart are common pathways connecting the two. Consequently, preventing infections through vaccination may indirectly reduce the incidence of heart attacks and strokes.

Public health officials argue that a unified policy could leverage existing vaccine infrastructure to deliver broader preventive benefits without significant additional cost. Critics caution that more evidence is needed to quantify the exact reduction in cardiovascular outcomes attributable to immunisation.

The European Commission’s investment in vaccine development signals confidence in technological progress, while the policy dialogue points to a parallel need for clear guidance on how these tools fit into cardiovascular disease prevention.

As the Parliament prepares to vote, the outcome will indicate whether vaccination against respiratory infections will be formally recognised as a component of the EU’s strategy to combat heart disease.